✉news WorldUS Politics first seen 4 h ago, last 20 min ago, peak #3
Sarepta Reports New ELEVIDYS Data in Older Duchenne Patients
Original: Sarepta Therapeutics Presents New Data at 2026 World Muscle Society Annual Congress Demonstrating Safety and Clinically Meaningful Functional Benefit of ELEVIDYS (delandistrogene moxeparvovec) in Older Ambulatory Patients with Duchenne
Sarepta Therapeutics presented new data at the 2026 World Muscle Society Annual Congress showing that ELEVIDYS (delandistrogene moxeparvovec) delivered safety results and clinically meaningful functional benefits in older ambulatory patients with Duchenne muscular dystrophy. The findings extend evidence for the gene therapy beyond the younger patient groups where it was first established, a development being watched closely by families, clinicians and investors tracking the company's expanding Duchenne franchise.
Why now: New clinical data on a leading Duchenne gene therapy was just presented at a major neuromuscular congress.
Sarepta TherapeuticsELEVIDYSWorld Muscle SocietyDuchenne muscular dystrophy
Rank over time, top of the chart is #1. 3 snapshots from 4 h ago to 20 min ago.
Evidence
API: https://socialmediatrends-api.osmike.com/v1/trends/489466